The histone lysineÂ­NÂ­methyltransferase 2A gene is also named for a subtype of this disease, due to the fact that rearrangements of it are associated with aggressive varieties of this condition.
The histone lysineÂ­NÂ­methyltransferase 2A gene is also named for a subtype of this disease, due to the fact that rearrangements of it are associated with aggressive varieties of this condition. The monosomy 7 cytogenetic abnormality is a poor prognostic indicator for a subtype of this disease, along with amplifications of the FLT3 gene. AllÂ­trans retinoic acid is used to treat one subtype of this disease. Adoptive therapy of CAR TÂ­cells are an experimental immunotherapy for this condition. "Secondary" forms of this condition arecaused by the radiation or chemotherapeutic treatment of other cancers. Although nowadays (*) methotrexate and 6Â­MP are used in the consolidation and maintenance phases of treatment, Sidney Farber pioneered the first chemotherapy drug aminopterin for the treatment of this cancer. One subtype of this cancer is caused by a 9Â­22 translocation characterized by the fusion BcrÂ­Abl oncogene; that is treated with imatinib, brand name Gleevec. For10 points, name this common cancer of the blood, which has lymphocytic and myelogenous forms.
The histone lysineÂ­NÂ­methyltransferase 2A gene is also named for a subtype of this disease, due to the fact that rearrangements of it are associated with aggressive varieties of this condition.
leukemia  [accept any subtype, such as  chronic  myelogenous  leukemia  (CML),  chronic  lymphocytic   leukemia  (CLL),  acute  myelogenous  leukemia  (AML),  acute  lymphocytic  leukemia  (ALL), or  hairy  cell   leukemia,   etc.; prompt on "cancer"]